Atumida Inc. is developing technologies that treat and reverse hemorrhagic shock. Founded in 2009, Atumida was a spin-off from Scott & White research in Temple and maintains formal relationships with the hospital system, Texas A&M, the University of Texas MD Anderson Cancer Center and Viral Genetics Inc. While Atumida’s technology belongs to Scott & White, Texas A&M maintains equity due to its contribution to initial business planning. Universities tend to focus on commercializing technology licensed from within their own institutions, making the Atumida a unique animal for Texas A&M.
